Tranzyme Pharma to Present TZP-102 Data at ADA June 8-12, 2012 in Philadelphia, PA
RESEARCH TRIANGLE PARK, N.C. – June 6, 2012 – Tranzyme Pharma (Nasdaq:TZYM), today announced that Niels Ejskjaer, M.D., Ph.D., Department of Medicine MEA (Endocrinology and Diabetes) Aarhus University Hospital, Aarhus Denmark will present a poster entitled TZP-102 Ghrelin Receptor Agonist Improves Symptoms of Diabetic Gastroparesis in Both Type 1 and Type 2 Diabetes, at the American Diabetes Association’s 72nd Scientific Sessions taking place at the Pennsylvania Convention Center, Philadelphia, PA from June 8-12, 2012. The general poster session is scheduled for Saturday, June 9, 2012 at 11:30 am ET, and the poster will be showcased as part of a Guided Audio Poster Tour on Monday, June 11, 2012 at 1:00 pm ET.
About Tranzyme Pharma
Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. This product candidate targets a significant underserved market. Enrollment in a multinational, Phase 2b trial is ongoing; top-line data are expected by year-end 2012. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.
Further information about Tranzyme Pharma can be found on the Company’s web site at www.tranzyme.com.